Analyse du premier contrôle des frottis ASC-US par les médecins généralistes en Maine-et-Loire en 2014 (notice n° 1004718)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04697cam a2200373 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250125135006.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Theurier, Laure |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Analyse du premier contrôle des frottis ASC-US par les médecins généralistes en Maine-et-Loire en 2014 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2018.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 90 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Introduction : Lors de l’étude, l’HAS recommandait 3 options de premier contrôle (C1) en cas de découverte d’un ASC-US sur un frottis de dépistage : un frottis à 6 mois, un test HPV ou une colposcopie.Notre objectif principal était de connaître l’option choisie du C1. Les objectifs secondaires étaient d’évaluer le nombre de C1 réalisés par les médecins généralistes, le taux de suivi et celui des comptes-rendus des frottis C1 adaptés. Méthode : Étude rétrospective descriptive, réalisée sur les données de CAP Santé 49 (organisme départemental du dépistage organisé des cancers), concernant les femmes de 25 à 65 ans ayant un frottis de dépistage avec un résultat ASC-US réalisé par un médecin généraliste. Résultats : 397 patientes incluses, 373 avec suivi soit 94 % dont 367 C1 et 6 traitements.Parmi les C1 : 212 frottis (57,76 %), 89 tests HPV (24,25 %), 40 colposcopies (10,9 %), 26 techniques couplées (7,08 %). 235 soit 64,03 % sont réalisés par les médecins généralistes, 130 soit 35,42 % par les gynécologues et 2 par les sages-femmes soit 0,54 %.Sur les 126 comptes-rendus de frottis normaux reçus par les médecins généralistes, 70,63 % renseignaient l’antécédent d’ASC-US. Parmi eux 14 soit 15,7 % précisaient un délai de contrôle conforme aux recommandations. Conclusion : Cette étude réalisée en 2014 montre le doublement des tests HPV par rapport à l’étude similaire de 2011. En décembre 2016, l’INCa a positionné ce test comme référence du contrôle des ASC-US. En 2018 débutera le dépistage organisé du cancer du col de l’utérus qui impliquera les médecins généralistes. Cette étude pourra servir de base pour évaluer les modifications de leur pratique. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Introduction: During the study, the HAS (French Board of Health) recommended 3 options for the first test (C1) in case of presence of ASC-US: a smear to be carried out after 6 months, an HPV test or a colposcopy.Our main objective was to find out which C1 option was chosen. The secondary objectives were to evaluate the number of C1’s carried out by general practitioners, the follow-up rate and that of adapted C1 smear reports. Method: Retrospective descriptive study based on the data obtained from CAP Santé 49 (departmental organization of cancer screening), concerning women between the ages of 25 and 65 years old having had a smear test with a positive ASC-US result carried out by a general practitioner. Results: Based on 397 female patients, 373 with a 94% follow-up of which 367 C1’s and 6 treatments. Among the C1’s: 212 smears (57.76%), 89 tests HPV (24.25%), 40 colposcopies (10.9%), 26 double techniques (7.08%). 235 representing 64.03% were carried out by general practitioners, 130 representing 35.42% by gynecologists and 2 representing 0,54% by midwives. Of the 126 normal smear reports received by general practitioners, 70.63% gave information about an ASC-US antecedent. Among them 14 representing 15.7% complied with the recommended specified time intervals. Conclusion: This study which was carried out in 2014 demonstrates that HPV tests have doubled compared to a similar study carried out in 2011. In December 2016, the INCa (French National Cancer Institute) qualified this test as being the reference test for ASC-US checks. In January 2018, general cervical cancer screening involving general practitioners will be carried out. This study will serve as a basis on which to evaluate their practices. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | dépistage |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | étude descriptive |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | médecine générale |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | frottis cervico-utérin |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Human Papilloma Virus |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | ASC-US |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cervical cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cervical pap smear |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | screening |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | descriptive study |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Human Papilloma Virus |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | ASC-US |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | general practice |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Tessier Cazeneuve, Christine |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Le Duc-Banaszuk |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Baron, Céline |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | de Casabianca, Catherine |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Santé Publique | 30 | 4 | 2018-10-22 | p. 499-505 | 0995-3914 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-sante-publique-2018-4-page-499?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-sante-publique-2018-4-page-499?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux